Ascendis Pharma A/S Announces Key Updates and Achievements in 2024
Business and Strategic Roadmap Update
Ascendis Pharma A/S (Nasdaq: ASND) has outlined its plans for 2025, emphasizing its position for rapid revenue growth. The company's President and CEO, Jan Mikkelsen, is set to present these updates at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025.
Participation in the 43rd Annual J.P. Morgan Healthcare Conference
Company executives will participate in the conference, with a live webcast available for investors. This event is a key platform for discussing Ascendis Pharma's strategic direction and future milestones.
Commercial Availability of YORVIPATH®
YORVIPATH® (palopegteriparatide), the first and only FDA-approved medicine for treating hypoparathyroidism in adults, is now available in the United States. This marks a significant milestone in the treatment of this condition.
New InsiGHTS Trial Results
Positive Week 26 topline results from the New InsiGHTS trial of TransCon™ hGH in Turner Syndrome have been announced. The trial achieved its primary objective, showing a safety and tolerability profile comparable to daily somatropin.
FDA Acceptance of Supplemental Biologics License Application
The FDA has accepted Ascendis Pharma's supplemental Biologics License Application for TransCon™ hGH for the treatment of adults with growth hormone deficiency, setting a PDUFA goal date of July 27, 2025.
Collaboration with Novo Nordisk
Ascendis Pharma has entered into a collaboration with Novo Nordisk for the development and commercialization of TransCon technology-based products in metabolic and cardiovascular diseases, leveraging Ascendis' proprietary technologies and Novo Nordisk's expertise.
Financial Results and Business Update
Ascendis Pharma reported its third quarter 2024 financial results, highlighting the launch of YORVIPATH in the U.S. and the planned NDA submission for TransCon CNP for achondroplasia. The company also provided a business update, discussing its financial health and strategic initiatives.
These updates and achievements underscore Ascendis Pharma's commitment to advancing its product pipeline and strategic partnerships, positioning the company for continued growth and success in the pharmaceutical industry.